Advertisement

Advertisement
Lung Cancer

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement...

Immunotherapy

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection...

Lung Cancer

Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC

Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence...


Advertisement
Lung Cancer

Using TROP2 Expression to Predict Outcomes in Advanced NSCLC

Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes...

 

Lung Cancer

NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC

The combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response...

Advertisement
Advertisement




Sponsored Content

SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY

Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Geriatric Oncology

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults

Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...

Advertisement

FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib/Letrozole Co-Pack for Early High-Risk Breast Cancer

On September 17, the U.S. Food and Drug Administration (FDA) approved the CDK4/6 inhibitor ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. The...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Global Cancer Care

IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting

It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...

Breast Cancer

A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar

Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...

Cancer Deaths of 5.5 Million Men Worldwide Have Led to 1.41 Million New Paternal Orphans

A preliminary report from the International Agency for Research on Cancer (IARC) revealed that, in 2020, 5.5 million men worldwide died from cancer, leading to 1.41 million new paternal orphans. The average age of the children at paternal death was 12 years old. The study by Guida et al is being...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Cardio-oncology
Lymphoma

New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer

In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...

Advertisement

Study Finds Nearly $70 Billion in Socioeconomic Losses Across 11 Countries Attributable to Ovarian Cancer

A study by Hutchinson et al quantifying the socioeconomic burden of ovarian cancer in 11 countries, including the United States, estimates that nearly $70 billion in socioeconomic losses may be attributable to ovarian cancer. Moreover, health expenditures to cover treatment in the first 2 years...

ASCO Post X Feed
Social Media Hub by Everwall